Vaccitech plc ADR (NASDAQ:VACC) saw an upside of 87.20% to $3.14 after adding $1.46 on Monday. The 5-day average trading volume is 1,844,800 shares of the company’s common stock. It has gained $4.3500 in the past week and touched a new high 3 times within the past 5 days. An average of 468,900 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 195,412.
VACC’s 1-month performance is 59.64% or $1.6550 on its low of $1.6400 reached on 09/25/23. The company’s shares have touched a 52-week low of $1.64 and high of $3.36, with the stock’s rally to the 52-week high happening on 09/25/23. YTD, VACC has achieved 33.83% or $1.3200 and has reached a new high 15 times. However, the current price is down -6.40% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
VACC stock investors last saw insider trading activity on Jun 26.Enright William (Chief Executive Officer) most recently sold 15,000 shares at $2.42 per share on Mar 27. This transaction cost the insider $36,298.
Valuation Metrics
VACC stock has a beta of 0.21. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.02 while the price-to-book (PB) in the most recent quarter is 0.56.
Vaccitech plc ADR’s quick ratio for the period ended June 29 was 15.26, with the current ratio over the same period at 15.26. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.05, while the total debt to equity was 0.06. The trailing 12-month EBITDA margin is -50.79% while for the period ending June 29, Vaccitech plc ADR’s operating margin was -390.43%. The firm’s gross profit as reported stood at $48.74 million against revenue of $44.7 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 165.92% to -$23.8 million, while revenue of -$18.18 million was 23.61% off the previous quarter. Analysts expected VACC to announce -$0.55 per share in earnings in its latest quarter, but it posted -$0.62, representing a -12.70% surprise. EBITDA for the quarter stood at more than -$25.04 million. VACC stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 28.67 million, with total debt at $12.18 million. Shareholders hold equity totaling $38.52 million.
Let’s look briefly at Vaccitech plc ADR (VACC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 89.95% to suggest the stock is trending Overbought, with historical volatility in this time period at 393.06%.
The stock’s 5-day moving average is $2.0941, reflecting a +115.25% or $1.9650 change from its current price. VACC is currently trading +82.13% above its 20-day SMA, +58.87% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +63.84% and SMA200 by+59.57%.
Stochastic %K and %D was 31.40% and 17.08% and the average true range (ATR) pointed at 0.3924. The RSI (14) points at 85.16%, while the 14-day stochastic is at 74.91% with the period’s ATR at 0.2902. The stock’s 9-day MACD Oscillator is pointing at 0.3971 and 0.4355 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Vaccitech plc ADR (NASDAQ: VACC), William Blair launched coverage with an Outperform rating. Analysts offering their rating for VACC stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate VACC as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 3 have offered a “buy” rating.
What is VACC’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.25 and a high of $15.00, with their median price target at $9.50. Looking at these predictions, the average price target given by analysts is for Vaccitech plc ADR (VACC) stock is $9.31.
